Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

Pilatus Biosciences Inc. Secures FDA Orphan Drug Designation for PLT012: A Breakthrough in Liver and Intrahepatic Bile Duct Cancer Treatment

DOVER, Del. and EPALINGES, Switzerland, Dec. 10, 2024 /PRNewswire/ -- Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Ach...

2024-12-11 11:04 2313

Pilatus Biosciences Inc. Secures FDA Orphan Drug Designation for PLT012: A Breakthrough in Liver and Intrahepatic Bile Duct Cancer Treatment

【2024 ASH】TransThera Announces the Phase I Study Results of TT-01488, a Novel Non-Covalent BTK Inhibitor, in Patients with Relapsed or Refractory B-cell Malignancies

NANJING, China and GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. (the "TransThera"), a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing innovative small molecule therapies for oncology, ...

2024-12-10 23:00 3239

Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released t...

2024-12-10 21:26 3457

Terumo Health Outcomes and Medis Medical Imaging Announce Strategic Partnership to Enhance Cardiovascular Care

– Collaboration combines Terumo's ePRISM™ precision medicine software platform withMedis' QFR® technology – SOMERSET, N.J., Dec. 10, 2024 /PRNewswire/ -- Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), and Medis Medical Imaging, a leading cardiac imaging software...

2024-12-10 21:00 2587

Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases

CAMBRIDGE, Mass., Dec. 9, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a collaboration with Kodiak Sciences Inc. (...

2024-12-10 10:18 2720

IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH

SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 9, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today shared findings via a poster ...

2024-12-10 10:00 3033

$IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH$

2024 ESMO Asia: TransThera announces clinical data of tinengotinib in combination with atezolizumab (PD-L1) in biliary tract carcinoma (BTC)

NANJING, China and GAITHERSBURG, Md., Dec. 9, 2024 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced the poster presentation at the 2024 European Society For Medical Oncology (ESMO) Asia Congress to discuss the clinical study of tinengotinib in combination with atezol...

2024-12-09 23:00 3816

Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial

* Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 * Appoints US-based Chief Commercial Officer, Andrew Udell * Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian media. SYDNEY, Dec. 9, 2024 /PRNewswire/ -- A...

2024-12-09 21:00 3397

Dizal Presents Latest Data of DZD8586, a LYN/BTK Dual Inhibitor, in B-cell Non-Hodgkin Lymphoma at the 2024 ASH Annual Meeting

DZD8586 demonstrated encouraging anti-tumor activity with manageable safety and favorable pharmacokinetic (PK) characteristics in patients with B-NHL SHANGHAI, Dec. 9, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment o...

2024-12-09 18:00 2656

2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting

SHANGHAI, Dec. 8, 2024 /PRNewswire/ -- December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients with chronic Graft-versus-Host Disease (cGvHD) who have either progressed or not responded to one or mo...

2024-12-09 10:40 2908

2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting

Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH

BEIJING, SHANGHAI and BOSTON, Dec. 8, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (Ame...

2024-12-09 08:42 2497

Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area

OSAKA, Japan and MONTREAL , Dec. 5, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters:Osaka, Japan; President: Toichi Takino; "Ono") announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics (Headquarters:Montreal, Quebec, Canada; CEO:...

2024-12-06 07:56 2487

China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke

NANJING, China, Dec. 4, 2024 /PRNewswire/ -- On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets), an innovative drug for stroke, has been approved for marketing by the National Medical Products Admini...

2024-12-04 18:10 4929

China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke

Akeso's Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer

HONG KONG, Dec. 4, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results from a prospective, open-label, single-arm, multi-center phase Ib/II clinical study (AK104-IIT-018) of cadonilimab (PD-1/CTLA-4 bispecific antibody) in patients with advanced or metastat...

2024-12-04 13:09 2853

VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery

* VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery * Statistically and clinically meaningful reductions in inflammation and ...

2024-12-04 00:00 3030

Terumo Interventional Systems Announces Launch of Its R2P NaviCross Peripheral Support Catheter

– Provides interventionalists with optimal product choices for more complex radial-to-peripheral procedures– SOMERSET, N.J., Dec. 3, 2024 /PRNewswire/ -- Terumo Interventional Systems (TIS), a division of Terumo Corporation, is pleased to announce the launch and commercial availability of its R2...

2024-12-03 21:00 2225

Samsung Biologics hosts ESG event with suppliers to strengthen decarbonization efforts

INCHEON, South Korea, Dec. 3, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today hosted its second Supplier ESG Day to share insights on sustainable management and encourage ESGactions among suppliers. Second of i...

2024-12-03 20:00 2654

Fangzhou Inc. Announces Inclusion of Its Shares in Hang Seng Hong Kong-Listed Biotech Index

HONG KONG, Dec. 3, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced today that the Company's Ordinary Shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), will be included in the Hang Seng Hong Ko...

2024-12-03 18:47 2642

MGI Tech announces partnership with Universidad de San Martín de Porres to strengthen human genetics research

* The implementation of MGI Tech's next-generation genomic sequencing (NGS) technologies will strengthen scientific research in the country, enabling the identification of key genetic variations, contributing to disease prevention, and personalizing medical treatments. * A team of specialists...

2024-12-02 11:16 2438

MGI Tech announces partnership with Universidad de San Martín de Porres to strengthen human genetics research

BGM Group Ltd Pioneers Innovation in AI Technology, Fostering Holistic Integration of Healthcare and Insurtech

CHENGDU, China, Nov. 29, 2024 /PRNewswire/ -- BGM Group Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), a leading global pharmaceutical enterprise, today announced its acquisition of the intelligent platform of AIX Inc. (NASDAQ: AIFU) ("AIX") valued at1 billion RMB (approximately $140 million). The ...

2024-11-29 23:58 6734

1 ... 65 66 676869 70 71 ... 165